Bioventus (BVS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.22
- Estimate
- $0.22
- Surprise
- +0.9%
- Revenue (period 2026-06-27)
- $153.2M
- Score at report (before → after)
- 5.6 → 5.6/10
Revenue source: xbrl.
How the report landed
Bioventus (BVS) reported diluted EPS of $0.22, in line with the $0.22 estimate. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Sell at 5.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BVS Hold at 5.8/10.
3 of the last 4 quarters beat the estimate; this quarter's +0.9% surprise compares with a +40.7% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Weak growth
- Momentum score 4.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.20
- Price target
- $15.31
- Stop
- $12.30
- Upside to target
- +16.0%
- Reward-to-risk
- 2.3:1
The stock trades at 16.9× trailing but 14.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
BVS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $888.0M
- P/E (fwd)
- 14.1
- P/E (ttm)
- 16.9
- 52-week range
- $6.25–$15.89
- Off 52-week high
- 16.9%
- RSI (14)
- 37
- Volume vs avg
- 1.02×
- Score today
- 5.8/10